{"id":30919,"date":"2014-09-11T08:25:17","date_gmt":"2014-09-11T12:25:17","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=30919"},"modified":"2014-09-11T08:25:17","modified_gmt":"2014-09-11T12:25:17","slug":"aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919","title":{"rendered":"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/11\/2014 (wallstreetpr) \u2013 The leading product candidate of <strong>Aradigm Corporation (NASDAQ:ARDM)<\/strong>, named as Pulmaquin got the fast track status from <a href=\"http:\/\/lungdiseasenews.com\/2014\/09\/10\/aradigms-novel-non-cystic-fibrosis-bronchiectasis-treatment-granted-fast-track-status-by-fda\/\" target=\"_blank\">FDA<\/a>. It is a drug for treating the patients suffering from chronic lung infections. The study of drug is in its phase 3 clinical trials.<\/p>\n<p style=\"text-align: justify;\"><strong>The indications<\/strong><\/p>\n<p style=\"text-align: justify;\">Acquiring the status of Fast Track designation holds significance importance for Aradigm Corporation (NASDAQ:ARDM). It will facilitate the development of drugs found for the treatment of life-threatening diseases. It will enable the manufacturers to focus more on development of drugs so as to fulfill the unmet medical needs of people. It can change the way the new drugs are delivered to the patients. The status is granted on a number of factors including day-to-day functioning, survival or the severity of the disease, which if left untreated can result into something more serious.<\/p>\n<p style=\"text-align: justify;\"><strong>The development<\/strong><\/p>\n<p style=\"text-align: justify;\">The status can be better defined as a key development as per which Aradigm can meet FDA more frequently to discuss the matters related with eligible drug like development plan, collection of data, Rolling review and many others.\u00a0Aradigm Corporation (NASDAQ:ARDM) don\u2019t have to wait for completion of every section of the application for the review process. It can complete the sections of NDA and can submit it for review to FDA. It makes a trickle-down effect for patients. In the case, drug is approved, it can reach the market sooner than planned.<\/p>\n<p style=\"text-align: justify;\"><strong>Management view<\/strong><\/p>\n<p style=\"text-align: justify;\">Juergen Froehlich, MD, stated that Aradigm is delighted to get a fast track status for Pulmaquin that will encourage the firm to meet medical needs. It already has Qualified Infectious Disease Product designation that allows Aradigm to develop treatment drug in non-CF BE patients suffering from chronic lung infections. QIDP status was granted earlier this year allowing Aradigm Corporation (NASDAQ:ARDM) to take benefits of certain drug development incentives made available by FDA. Pulmaquin studies is running in two phase III clinical trials. The status will further speed up review of NDA submission.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/11\/2014 (wallstreetpr) \u2013 The leading product candidate of Aradigm Corporation (NASDAQ:ARDM), named as Pulmaquin got the fast track status from FDA. It is [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":30929,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264,263],"tags":[8985,8984,8986],"stock_ticker":[],"class_list":["post-30919","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-technology","tag-aradigm-corporation-nasdaqardm","tag-juergen-froehlich","tag-nasdaqardm","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/11\/2014 (wallstreetpr) \u2013 The leading product candidate of Aradigm Corporation (NASDAQ:ARDM), named as Pulmaquin got the fast track status from FDA. It is [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-11T12:25:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"100\" \/>\n\t<meta property=\"og:image:height\" content=\"40\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA\",\"datePublished\":\"2014-09-11T12:25:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg\",\"keywords\":[\"Aradigm Corporation (NASDAQ:ARDM)\",\"Juergen Froehlich\",\"NASDAQ:ARDM\"],\"articleSection\":[\"Health\",\"Technology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919\",\"name\":\"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg\",\"datePublished\":\"2014-09-11T12:25:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg\",\"width\":100,\"height\":40},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919","og_locale":"en_US","og_type":"article","og_title":"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA - Wall Street PR","og_description":"Boston, MA 09\/11\/2014 (wallstreetpr) \u2013 The leading product candidate of Aradigm Corporation (NASDAQ:ARDM), named as Pulmaquin got the fast track status from FDA. It is [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-11T12:25:17+00:00","og_image":[{"width":100,"height":40,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA","datePublished":"2014-09-11T12:25:17+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg","keywords":["Aradigm Corporation (NASDAQ:ARDM)","Juergen Froehlich","NASDAQ:ARDM"],"articleSection":["Health","Technology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919","url":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919","name":"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg","datePublished":"2014-09-11T12:25:17+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/images19.jpg","width":100,"height":40},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/aradigm-corporation-nasdaqardms-pulmaquin-gets-fast-track-status-from-fda-30919#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Aradigm Corporation (NASDAQ:ARDM)\u2019s Pulmaquin Gets Fast Track Status From FDA"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=30919"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30919\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/30929"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=30919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=30919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=30919"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=30919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}